| 54 |
Title |
TI |
[EN] USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] FOR THE TREATMENT OF CANCER
[FR] UTILISATION DE TRANS-[TÉTRACHLOROBIS(1H-INDAZOLE)RUTHÉNATE (III)] POUR LE TRAITEMENT DU CANCER |
| 71/73 |
Applicant/owner |
PA |
INTEZYNE TECH, US
|
| 72 |
Inventor |
IN |
BAKEWELL SUZANNE, US
;
KEPPLER BERNHARD K, DE
;
SETHURAMAN JYOTHI, US
|
| 22/96 |
Application date |
AD |
Mar 1, 2017 |
| 21 |
Application number |
AN |
2017020190 |
|
Country of application |
AC |
US |
|
Publication date |
PUB |
Sep 8, 2017 |
33
31
32 |
Priority data |
PRC
PRN
PRD |
US
201662301786
20160301
|
| 51 |
IPC main class |
ICM |
A01N 55/02
(2006.01)
|
| 51 |
IPC secondary class |
ICS |
A61K 31/28
(2006.01)
A61K 31/416
(2006.01)
A61K 31/555
(2006.01)
A61K 33/24
(2006.01)
A61K 38/16
(2006.01)
A61P 35/00
(2006.01)
C07K 16/18
(2006.01)
|
|
IPC additional class |
ICA |
|
|
IPC index class |
ICI |
|
|
Cooperative patent classification |
CPC |
A61K 2039/505
A61K 2300/00
A61K 31/28
A61K 31/416
A61K 31/555
A61K 31/7068
A61K 33/24
A61K 39/39541
A61K 39/3955
A61K 45/06
A61P 35/00
C07K 16/2818
C07K 2317/73
|
|
MCD main class |
MCM |
A01N 55/02
(2006.01)
|
|
MCD secondary class |
MCS |
A61K 31/28
(2006.01)
A61K 31/416
(2006.01)
A61K 31/555
(2006.01)
A61K 33/24
(2006.01)
A61K 38/16
(2006.01)
A61P 35/00
(2006.01)
C07K 16/18
(2006.01)
|
|
MCD additional class |
MCA |
|
| 57 |
Abstract |
AB |
[EN] IT-139, sodium trans-[tetrachlorobis(1H-indazole)ruthenate (III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from IT-139's novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemotherapy and immuno-oncology agents to be more effective in treating cancer.
[FR] Selon la présente invention, IT-139, trans-[tétrachlorobis(1H-indazole)ruthénate (III) de sodium], est un composé à petite molécule administré par voie intraveineuse. Dans des études précliniques anticancéreuses et de mécanisme d'action, IT-139 à présenter une activité contre une large gamme de type de tumeur, y compris celles qui sont résistantes aux agents anticancéreux standards (par exemple, platines, alcaloïdes de pervenche, taxanes, anthracyclines). Il est estimé que cette activité est liée au nouveau mécanisme d'action d'IT-139 qui cible la voie GRP78. Il a été découvert que la régulation positive de GRP78 est une voie clé de survie des cellules cancéreuses. La régulation négative de GRP78 au moyen d'IT-139 élimine cette voie de résistance, de façon à permettre que des agents chimiothérapeutiques et d'immuno-oncologie soient plus efficaces dans le traitement du cancer. |
| 56 |
Cited documents identified in the search |
CT |
US000009089578B2
WO002008154553A1
WO002016029073A2
|
| 56 |
Cited documents indicated by the applicant |
CT |
|
| 56 |
Cited non-patent literature identified in the search |
CTNP |
IT -139: A NOVEL GRP78 INHIBITOR, 27 October 2016 (2016-10-27), Retrieved from the Internet [retrieved on 20170414] 7
|
| 56 |
Cited non-patent literature indicated by the applicant |
CTNP |
|
|
Citing documents |
|
Determine documents
|
|
Sequence listings |
|
|
|
Search file IPC |
ICP |
A01N 55/02
A61K 31/28
A61K 31/416
A61K 31/555
A61K 33/24
A61K 38/16
A61K 51/04
A61P 35/00
C07K 16/18
C07K 16/28
|
